References
- 1. Lai T, Liu S, Das S, Lam D. Intravitreal Injections – Technique and Safety // Asia Pac J Ophthalmol, 2015; 4:321–328
- 2. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of antiVEGF agents: a review of literature // Eye, 2013, 27(7):787–79410.1038/eye.2013.107370938523722722
- 3. Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden of Treatment Among Patients Undergoing Intravitreal Injections for Diabetic Oedema in Australia // Diabetes Metab Syndr Obes, 2019; 12:1931–1921
- 4. Sii S, Aspinall P, Borooah S, Dhillon B. Exploring factors predicting changes in patients’ expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age–related macular degeneration // Eye, 2017, 32(4):673–67810.1038/eye.2017.271589885629219960
- 5. Wu Y, Ai P, Ai Z, Xu G. Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with antiVEGF therapy for diabetic macular edema: A Bayesian network meta–analysis // Biomed Pharmacother, 2018, (97):293–29910.1016/j.biopha.2017.10.07829091878
- 6. Akhlaghi M, Dehghani A et al. Effects of subthreshold diode micropulse laser photocoagulation on treating patients with refractory diabetic macular edema // J Curr Ophthalmology, 2018, 31(2): 157–16010.1016/j.joco.2018.11.006661192331317093
- 7. Gonzales–Saldivar G, Rojas–Juarez S, Espinosa–Soto I et al. Single–Spot Yellow Laser Versus Conventional Green Laser on Panretinal Photocoagulation: Patient PAin Scores and Preferences // Ophthalmic Surg Lasers Imaging Retina, 2017, 48(11):902–90510.3928/23258160-20171030-0529121359
- 8. Parodi M B, Iacono P, Bandello F. Subthreshold grid laser versus intravitreal bevacizumab as a second line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment // Graefes Arch Clin Exp Ophthalmol, 2015, (10):1647–165110.1007/s00417-014-2845-625382074
- 9. Lim LS, Cheung CMG, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti–VEGF agents – should ophthalmologists be concerned? // Am J Ophthalmol, 2011 152(3): 329–3310.1016/j.ajo.2011.05.04021855670